Novartis' CEO warned Tuesday that U.S. drug pricing policy under President Donald Trump poses a "very difficult situation." ...

Novartis CEO says Trump drug pricing impact will intensify over 18 months, affecting sales and access to new medicines globally.

Novartis CEO Vas Narasimhan is doubling down on his $5 billion peak sales projection for Pluvicto, even as the company has ...

Novartis is “continuing to evaluate” the in vivo CAR-T space, although the pharma’s CEO has told Fierce Biotech that no deals ...

On Tuesday, Novartis NVS CEO Vas Narasimhan said the Trump administration's "most favored nation" (MFN) drug pricing policy ...

Novartis CEO Vas Narasimhan says Europe needs a “complete rethink” of how it prices its drugs, warning that the entrance of ...

Novartis, a Swiss pharmaceutical company, named its Global Head of Drug Development and CMO Vasant Narasimhan, MD, successor to current CEO Joe Jimenez, who will step down Jan. 31. Here are five notes ...

Novartis will add a new North Carolina facility for active pharmaceutical ingredient (API) manufacturing for solid dosage ...

LONDON (Reuters) -Swiss drugmaker Novartis on Monday defended its $12 billion deal to acquire Avidity Biosciences ahead of the U.S. firm getting late-stage data for its muscle disorder treatment next ...

The site is expected to be operational in 2028, adding new roles in advanced manufacturing and bioengineering.